Next Step in Emerson's Portfolio
Transformation, Diversifying Technology Into Test and Measurement
Automation
Provides Enhanced Automation Capabilities and
Expansion Into Diverse, High-Growth Discrete End Markets
Significant Opportunities to Create
Shareholder Value Through $165
Million of Cost Synergies
Accelerates Underlying Revenue Growth, Expands
Gross Margins, Accretive to Adjusted Earnings in Year One and Meets
Communicated Return Criteria
Emerson Reaffirms Second Quarter
Guidance
Emerson to Host Conference Call to Discuss
Transaction Today at 8:30 a.m. Eastern
Time / 7:30 a.m. Central
Time
ST.
LOUIS and AUSTIN,
Texas, April 12, 2023 /PRNewswire/ -- Emerson
(NYSE: EMR) and NI (Nasdaq: NATI) today announced that they have
entered into a definitive agreement under which Emerson will
acquire NI for $60 per share in cash
at an equity value of $8.2 billion.
Emerson already owns approximately 2.3 million shares of NI,
representing approximately 2% of shares outstanding, which were
acquired at a weighted average price of $36.84. As a result, Emerson's effective per
share purchase price is $59.61.

NI provides software-connected automated test and measurement
systems that enable enterprises to bring products to market faster
and at a lower cost. NI's solutions help customers solve current
and future test challenges and improve speed and efficiency in
their product development cycles. NI had $1.66 billion in 2022 revenue and operates in
more than 40 countries, serving approximately 35,000 customers
across semiconductor and electronics, transportation, and aerospace
and defense markets.
"We are pleased to reach an agreement with NI, whose
best-in-class test and measurement product and software offerings
accelerate Emerson's progress toward a cohesive, higher growth and
higher margin automation portfolio," said Lal Karsanbhai, President
and Chief Executive Officer of Emerson. "With this expansion into
test and measurement, Emerson will enhance its automation
capabilities and gain a broader set of customers that relies on
NI's solutions at critical points along the product development
cycle. These capabilities provide Emerson industry diversification
into attractive and growing discrete markets like semiconductor and
electronics, transportation and electric vehicles, and aerospace
and defense that are poised to benefit from secular growth trends.
NI's business is well-aligned with our vision for automation and we
look forward to working together to bring more comprehensive and
innovative solutions to our customers, accelerate growth and
position Emerson to deliver significant shareholder value."
"Over the past several months, we've been evaluating strategic
options for the future of our business with the intent to maximize
its value," said Eric Starkloff,
NI's Chief Executive Officer. "We ran a robust and comprehensive
process, considered a range of potential options, and believe this
represents the best outcome for all NI stakeholders. This
transaction is a strong testament to the improvements and
initiatives we've implemented in recent years that have transformed
NI into a software focused company with higher growth, better
profitability and lower cyclicality. We're thrilled that Emerson
recognizes the value we've created and we believe they will help us
build on our momentum to further position NI as a leading provider
of software-connected automated test and measurement systems."
Compelling Strategic and Financial Rationale
- Balanced and Diversified End Markets: With
favorable long-term trends and an estimated priority total
addressable market of $35 billion,
the test and measurement market is fast-growing, highly
complementary and one of the four priority adjacencies Emerson
presented at its 2022 Investor Conference. The transaction is
expected to drive value creation and advance Emerson's position as
a global automation leader by expanding and diversifying its
customer base within highly attractive end markets. With a
diversified end market mix including semiconductor and electronics,
transportation, and aerospace and defense, NI is expected to be
well positioned to capitalize on megatrends that offer attractive
growth opportunities. In markets like semiconductor and electric
vehicle manufacturing, NI expands Emerson's reach into the design
and validation phase of the lifecycle, providing early access to
customers. Overall, NI will increase Emerson's end market exposure
in discrete markets to 18% of sales, which will be Emerson's second
largest industry segment.
- Complementary Software and Innovation
Capabilities: NI's technology stack of industry-leading
intelligent devices, controls and software complements Emerson's
own technology stack and will accelerate Emerson's efforts to
create a higher value, cohesive industrial technology portfolio.
NI's flexible and modular system-level test solutions have an open
and interoperable software platform, a key differentiator that
enables customers to continually evolve and automate their test
processes in increasingly complex and fast-changing end markets.
With 20% of sales in software, NI also increases Emerson's exposure
to high-growth industrial software opportunities. Both Emerson and
NI share innovation-focused engineering cultures. With Emerson's
proven track record of innovation and successful new product
launches, the combined company will be able to accelerate and
expand the development of innovative offerings for customers
leveraging the complementary expertise of both organizations.
- Delivers Substantial Synergies: Emerson has identified
$165 million of cost synergy
opportunities by the end of year 5 through application of best
practices from the Emerson Management System. Emerson intends to
drive productivity improvements and streamline duplicative costs
across general and administrative, sales and marketing, and
research and development functions, while leveraging Emerson's
scale in manufacturing and supply chain. Additional opportunities
to enhance NI's free cash flow generation will be pursued through
proven operational excellence and productivity levers.
- Strong Financial Profile and Attractive Returns for
Shareholders: The transaction is expected to be immediately
accretive to adjusted EPS and Emerson's long-term financial targets
outlined at Emerson's 2022 Investor Conference. NI's strong
positions in attractive and growing markets are expected to deliver
sustainable underlying growth aligned to Emerson's 4-7%
through-the-cycle underlying growth target. NI also brings
significant recurring revenue and immediate gross margin accretion
to the combined Emerson portfolio. The combination of strong
growth, attractive gross margins and the synergy potential to
expand operating margins all contribute to returns in line with
Emerson's communicated returns criteria.
- Unites Aligned Company Cultures: NI's innovation and
problem-solving focused culture is highly complementary with
Emerson's purpose-driven culture focused on innovation. Employees
will have expanded opportunities for career development and
advancement within Emerson.
Transaction Terms & Approvals
The transaction has been approved by the Boards of Directors of
both Emerson and NI. Under the terms of the agreement, NI
shareholders will receive $60 per
share in cash, which represents a 49% premium to NI's closing share
price as of January 12, 2023, the day
prior to NI's public announcement of a strategic review.
The transaction is expected to close in the first half of
Emerson's fiscal 2024, subject to the completion of customary
closing conditions, including regulatory approvals and approval by
NI shareholders. Emerson expects to finance the transaction using
available cash and liquidity, including approximately $8 billion of post-tax proceeds from the majority
sale of Climate Technologies to Blackstone announced in
October 2022, which is expected to
close in the second calendar quarter of 2023.
Emerson Reaffirms Second Quarter 2023 Guidance
On February 8, 2023, Emerson
provided continuing operations second quarter underlying sales
growth guidance of 8%-10% and adjusted earnings per share guidance
of $0.95-$1.00. Emerson is reaffirming this guidance.
Investor Conference Call and Presentation
Emerson management will discuss the transaction during an
investor conference call today, April 12,
2023, beginning at 7:30 a.m. Central
Time / 8:30 a.m. Eastern Time.
Participants can access a live webcast available
at www.Emerson.com/en-us/investors at the time of the
call. A replay of the call will be available for 90 days.
Conference call slides will be posted in advance of the call.
NI plans to release its first quarter fiscal year 2023 results
after market close on April 27, 2023.
Given the pending acquisition of NI by Emerson, NI will not host an
earnings conference call for first quarter results.
Advisors
Goldman Sachs & Co. LLC and Centerview Partners LLC are
serving as financial advisors to Emerson
and Davis Polk & Wardwell LLP is serving as legal
advisor. BofA Securities is serving as exclusive financial advisor
to NI and Wachtell, Lipton, Rosen & Katz is serving as legal
advisor.
About Emerson
Emerson (NYSE: EMR) is a global
technology and software company providing innovative solutions for
the world's essential industries. Through its leading automation
portfolio, including its majority stake in AspenTech, Emerson helps
hybrid, process and discrete manufacturers optimize operations,
protect personnel, reduce emissions and achieve their
sustainability goals. For more information,
visit Emerson.com.
About NI
At NI, we bring together people, ideas and
technology so forward thinkers and creative problem solvers can
take on humanity's biggest challenges. From data and automation to
research and validation, we provide the tailored,
software-connected systems engineers and enterprises need to
Engineer Ambitiously™ every day.
National Instruments, NI
and ni.com and Engineer Ambitiously are
trademarks of National Instruments Corporation. Other product
and company names listed are trademarks or trade names of their
respective companies. (NATI-F)
Additional Information and Where to Find It
This communication relates to a proposed business combination
transaction between Emerson and NI (the "Proposed Transaction").
This communication does not constitute an offer to buy or sell or
the solicitation of an offer to buy or sell any securities or a
solicitation of any vote or approval. In connection with the
Proposed Transaction, NI may file one or more proxy statement(s) or
other documents with the SEC. This communication is not a
substitute for any proxy statement NI may file with the SEC in
connection with the Proposed Transaction.
BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND
SECURITY HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY
THE PROXY STATEMENT(S) AND/OR OTHER DOCUMENTS IF AND WHEN THEY ARE
FILED, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS,
IN CONNECTION WITH THE PROPOSED TRANSACTION, BECAUSE THESE
DOCUMENTS CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
PROPOSED TRANSACTION AND RELATED MATTERS. Any definitive proxy
statement (if and when available) will be mailed or otherwise made
available to stockholders of NI. Investors and security holders
will be able to obtain free copies of these documents filed with
the SEC if and when available without charge through the website
maintained by the SEC at www.sec.gov or, in the case of documents
filed by NI, by directing a request to National Instruments
Corporation, 11500 North Mopac Expressway, Austin, Texas 78759, Attention: Investor
Relations; telephone (512) 683-5215, or from NI's website
www.ni.com, or, in the case of documents filed by Emerson, by
contacting the investor relations department of Emerson:
Emerson
8000 West Florissant Avenue, P.O. Box 4100
St. Louis, MO
www.emerson.com/en-us/investors
Investor Relations:
Colleen Mettler, Vice
President
(314) 553-2197
investor.relations@emerson.com
Participants in the Solicitation
Emerson and certain of its directors and executive officers may
be deemed to be participants in the solicitation of proxies in
connection with the Proposed Transaction.
Information regarding the persons who may, under the rules of
the SEC, be deemed participants in the solicitation of proxies in
connection with the Proposed Transaction, including a description
of their direct or indirect interests in the transaction, by
security holdings or otherwise, will be set forth in any proxy
statement(s) and other relevant materials related to the Proposed
Transaction if and when they are filed with the SEC. Information
regarding the directors and executive officers of Emerson is
contained in Emerson's proxy statement for its 2023 annual meeting
of stockholders, filed with the SEC on December 9, 2022 and its Annual Report on Form
10-K for the year ended September 30,
2022, which was filed with the SEC on November 14, 2022. To the extent holdings of
Emerson securities by the directors and executive officers of
Emerson have changed from the amounts of securities of Emerson held
by such persons as reflected therein, such changes have been or
will be reflected on Statements of Change in Ownership on Form 4
filed with the SEC. These documents can be obtained free of charge
from the sources indicated above.
NI and certain of its directors, executive officers and
employees may be deemed to be participants in the solicitation of
proxies in respect of the Proposed Transaction. Information
regarding NI's directors and executive officers is available in
NI's proxy statement for the 2023 annual meeting of stockholders,
which was filed with the SEC on March
27, 2023. Other information regarding the participants
in the proxy solicitation and a description of their direct and
indirect interests, by security holdings or otherwise, will be
contained in the proxy statement(s) filed by NI and other relevant
materials to be filed with the SEC in connection with the Proposed
Transaction when they become available. Free copies of such proxy
statement(s) and such other materials may be obtained as described
in the preceding section.
Caution Concerning Forward-Looking Statements of Emerson
This communication contains "forward-looking" statements as that
term is defined in Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. All
statements, other than historical facts, are forward-looking
statements, including: statements regarding the expected timing and
structure of the Proposed Transaction; the ability of the parties
to complete the Proposed Transaction; the expected benefits of the
Proposed Transaction, such as improved operations, enhanced
revenues and cash flow, synergies, growth potential, market
profile, business plans, expanded portfolio and financial strength;
the competitive ability and position of Emerson following
completion of the Proposed Transaction; legal, economic and
regulatory conditions; and any assumptions underlying any of the
foregoing. Forward-looking statements concern future circumstances
and results and other statements that are not historical facts and
are sometimes identified by the words "may," "will," "should,"
"potential," "intend," "expect," "endeavor," "seek," "anticipate,"
"estimate," "overestimate," "underestimate," "believe," "plan,"
"could," "would," "project," "predict," "continue," "target" or
other similar words or expressions or negatives of these words, but
not all forward-looking statements include such identifying words.
Forward-looking statements are based upon current plans, estimates
and expectations that are subject to risks, uncertainties and
assumptions. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those indicated or
anticipated by such forward-looking statements. Emerson can give no
assurance that such plans, estimates or expectations will be
achieved and therefore, actual results may differ materially from
any plans, estimates or expectations in such forward-looking
statements. Important factors that could cause actual results to
differ materially from such plans, estimates or expectations
include, among others: (1) that one or more closing conditions to
the Proposed Transaction, including certain regulatory approvals,
may not be satisfied or waived, on a timely basis or otherwise,
including that a governmental entity may prohibit, delay or refuse
to grant approval for the consummation of the Proposed Transaction,
may require conditions, limitations or restrictions in connection
with such approvals or that any required approval by the
stockholders of NI may not be obtained; (2) the risk that the
Proposed Transaction may not be completed in the time frame
expected, or at all; (3) unexpected costs, charges or expenses
resulting from the Proposed Transaction; (4) uncertainty of the
expected financial performance of NI following completion of the
Proposed Transaction; (5) failure to realize the anticipated
benefits of the Proposed Transaction, including as a result of
delay in completing the Proposed Transaction or integrating the
business of NI with the business of Emerson; (6) the ability of
Emerson to implement its business strategy; (7) difficulties and
delays in achieving revenue and cost synergies; (8) inability to
retain and hire key personnel; (9) the occurrence of any event that
could give rise to termination of the Proposed Transaction; (10)
potential litigation in connection with the Proposed Transaction or
other settlements or investigations that may affect the timing or
occurrence of the contemplated transaction or result in significant
costs of defense, indemnification and liability; (11) evolving
legal, regulatory and tax regimes; (12) changes in economic,
financial, political and regulatory conditions, in the United States and elsewhere, and other
factors that contribute to uncertainty and volatility, natural and
man-made disasters, civil unrest, pandemics (e.g., the coronavirus
(COVID-19) pandemic (the "COVID-19 pandemic")), geopolitical
uncertainty, and conditions that may result from legislative,
regulatory, trade and policy changes associated with the current or
subsequent U.S. administration; (13) the ability of Emerson and NI
to successfully recover from a disaster or other business
continuity problem due to a hurricane, flood, earthquake, terrorist
attack, war, pandemic, security breach, cyber-attack, power loss,
telecommunications failure or other natural or man-made event,
including the ability to function remotely during longterm
disruptions such as the COVID-19 pandemic; (14) the impact of
public health crises, such as pandemics (including the COVID-19
pandemic) and epidemics and any related company or governmental
policies and actions to protect the health and safety of
individuals or governmental policies or actions to maintain the
functioning of national or global economies and markets, including
any quarantine, "shelter in place," "stay at home," workforce
reduction, social distancing, shut down or similar actions and
policies; (15) actions by third parties, including government
agencies; (16) potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the
transaction; (17) the risk that disruptions from the Proposed
Transaction will harm Emerson's and NI's business, including
current plans and operations; (18) certain restrictions during the
pendency of the acquisition that may impact Emerson's or NI's
ability to pursue certain business opportunities or strategic
transactions; (19) the ability to meet expectations regarding the
accounting and tax treatments of the Proposed Transaction; and (20)
other risk factors as detailed from time to time in Emerson's
reports filed with the SEC, including Emerson's annual report on
Form 10-K, periodic quarterly reports on Form 10-Q, periodic
current reports on Form 8-K and other documents filed with the SEC.
While the list of factors presented here is considered
representative, no such list should be considered to be a complete
statement of all potential risks and uncertainties. Unlisted
factors may present significant additional obstacles to the
realization of forward-looking statements. Any forward-looking
statements speak only as of the date of this communication. Emerson
undertakes no obligation to update any forward-looking statements,
whether as a result of new information or development, future
events or otherwise, except as required by law. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements.
Caution Concerning Forward-Looking Statements of NI
This press release contains "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Exchange Act that are subject to
risks and uncertainties. These statements include those set
forth above relating to the Proposed Transaction, the expected
timing and structure of the Proposed Transaction; the ability of
the parties to complete the Proposed Transaction; the expected
benefits of the Proposed Transaction, such as improved operations,
enhanced revenues and cash flow, synergies, growth potential,
market profile, business plans, expanded portfolio and financial
strength; legal, economic and regulatory conditions; and any
assumptions underlying any of the foregoing, as well as those that
may be identified by words such as "believe," "expect," "plan,"
"may," "could," "will," "intend to," "project," "predict,"
"anticipate," "continue," "seek to," "strive to," "endeavor to,"
"are committed to," "remain committed to," "focus on," "are
encouraged by," "remain cautious," "remain optimistic" or
"estimate"; statements of "goals," "initiatives," "commitments,"
"strategy", "focus" or "visions"; or other variations thereof or
comparable terminology or the negative thereof. All
forward-looking statements are based on current expectations and
projections of future events. NI claims the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 for all forward-looking
statements. Although NI believes that the expectations
reflected in the forward-looking statements are reasonable,
forward-looking statements are not guarantees of performance and
actual results could differ materially from those projected in the
forward-looking statements as a result of a number of important
factors which could affect NI's future results and could cause
those results or other outcomes to differ materially from those
expressed or implied in the forward-looking statements. Risks
and uncertainties include without limitation: the global shortage
of key components; effect of the global economic and geopolitical
conditions; NI's international operations and foreign economies;
adverse public health matters, including epidemics and pandemics
such as the COVID-19 pandemic; NI's ability to effectively manage
its partners and distribution channels; interruptions in NI's
technology systems or cyber-attacks on its systems; the dependency
of NI's product revenue on certain industries and the risk of
contractions in such industries; concentration of credit risk and
uncertain conditions in the global financial markets; NI's ability
to compete in markets that are highly competitive; NI's ability to
release successful new products or achieve expected returns; the
risk that NI's manufacturing capacity and a substantial majority of
its warehousing and distribution capacity are located outside of
the U.S.; NI's dependence on key suppliers and distributors; longer
delivery lead times from NI's suppliers; risk of product liability
claims; dependence on NI's proprietary rights and risks of
intellectual property litigation; the continued service of key
management, technical personnel and operational employees; NI's
ability to comply with environmental laws and associated costs;
NI's ability to maintain its website; the risks of bugs,
vulnerabilities, errors or design flaws in NI's products; NI's
restructuring activities; NI's exposure to large orders; NI's shift
to more system orders; NI's ability to effectively manage its
operating expenses and meet budget; fluctuations in NI's financial
results due to factors outside of its control; NI's outstanding
debt; the interest rate risk associated with NI's variable rate
indebtedness; seasonal variation in NI's revenues; NI's ability to
comply with laws and regulations; changes in tax rates and exposure
to additional tax liabilities; NI's ability to make certain
acquisitions or dispositions, integrate the companies we acquire or
separate the companies we sold and/or enter into strategic
relationships; risks related to currency fluctuations; provisions
in charter documents and Delaware
law that delay or prevent NI's acquisition; the timing, receipt and
terms and conditions of any required governmental and regulatory
approvals of the Proposed Transaction that could cause the parties
to terminate the merger agreement; the occurrence of any event,
change or other circumstances that could give rise to the
termination of the merger agreement entered into pursuant to the
Proposed Transaction; the possibility that NI's stockholders may
not approve the Proposed Transaction; the risk that the parties to
the merger agreement may not be able to satisfy the conditions to
the Proposed Transaction in a timely manner or at all; risks
related to disruption of management time from ongoing business
operations due to the Proposed Transaction; the risk that any
announcements relating to the Proposed Transaction could have
adverse effects on the market price of NI's common stock; the risk
of any unexpected costs or expenses resulting from the Proposed
Transaction; the risk of any litigation relating to the Proposed
Transaction; the risk that the Proposed Transaction and its
announcement could have an adverse effect on the ability of NI to
retain customers and retain and hire key personnel and maintain
relationships with customers, suppliers, employees, stockholders
and other business relationships and on its operating results and
business generally; and the risk the pending Proposed Transaction
could distract management of NI. NI directs readers to its
Form 10-K for the year ended December 31,
2022 its subsequent Form 10-Qs, and the other documents it
files with the SEC for other risks associated with NI's future
performance. These documents contain and identify important
factors that could cause NI's actual results to differ materially
from those contained in NI's forward-looking statements. All
information in this press release is as of the date above. NI
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in NI's
expectations.
Reconciliations of Non-GAAP Financial
Measures – Emerson:
|
|
2023E February
Guidance Underlying Sales Change
|
Q2
FY23E
|
Reported
(GAAP)
|
10.5% -
12.5%
|
(Favorable) /
Unfavorable FX
|
~ 3%
|
(Acquisitions) /
Divestitures
|
~ (5.5)%
|
Underlying
(Non-GAAP)
|
8% - 10%
|
|
|
|
2023E February
Guidance Earnings Per Share
|
Q2
FY23E
|
Earnings per share
(GAAP)
|
$0.75 -
$0.80
|
Amortization of
intangibles
|
~ 0.15
|
Restructuring and
related costs
|
~ 0.05
|
Adjusted earnings per
share (Non-GAAP)
|
$0.95 -
$1.00
|
|
Contacts
For Emerson:
Investors
Colleen Mettler
314-553-2197
Media
Jim Golden / Joseph Sala / Tanner
Kaufman
Joele Frank, Wilkinson Brimmer
Katcher
212-355-4449
For NI:
Investor Relations
Marissa Vidaurri
Vice President, Investor Relations, NI
512-773-0856
marissa.vidaurri@NI.com
Media
John Christiansen / Pete Siwinski / Danya
Al-Qattan
FGS Global
NI@fgsglobal.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/emerson-to-advance-global-automation-leadership-through-acquisition-of-ni-301795491.html
SOURCE Emerson